

DAFTAR PUSTAKA

- Ambati, B.K, Nozaki, M., Singh, N., et al. 2006. Corneal avascularity is due to soluble VEGF receptor-1. *Nature*. 2006;443:993–7.
- Bachman, B., Taylor, R.S., Cursiefien, C. 2013. The association between corneal neovascularization and visual acuity: a systematic review. *Acta Ophthalmol*; 91(1):12-9.
- Baratawidjaja, K.G. 2012. *Imunologi Dasar*. Edisi 10. Jakarta : Balai penerbit Fakultas kedokteran Universitas Indonesia.
- Bartels, M.C., Doxiadis, I.I., Colen, T.P., et al. 2003. Long-term outcome in high-risk corneal transplantation and the influence of HLA-A and HLA-B matching. *Cornea*; 22(6):552-6.
- Beebe, D.C.. 2008. Maintaining transparency: a review of the developmental physiology and pathophysiology of two avascular tissues. *Semin Cell Dev Biol*; 19(2):125-33.
- Chang, J. H., Gabison, E. E., Kato, T. and Azar, D. T. 2001. Corneal neovascularization. *Curr. Opin. Ophthalmol*; 12, 242–249.
- Chaoran, Z., Zhirong, L., Gezhi, X. 2011. Combination of vascular endothelial growth factor receptor/platelet--derived growth factor receptor inhibition markedly improves the antiangiogenic efficacy for advanced stage mouse corneal neovascularization. *Graefes Arch Clin Exp Ophthalmol*; 249(10):1493--501
- Cursiefen, C., Kuchle, M., and Naumann, G. O. 1998 . Angiogenesis in corneal diseases: histopathologic evaluation of 254 human corneal buttons with neovascularization. *Cornea* 17, 611–613.
- David, M.J., Dominguez, C., Hamilton, D.H., et al. 2016. The IL-8/IL-8R Axis: A Double Agent in Tumor Immune Resistance. *Vaccines*; 24;4(3):22.
- Dastjerdi. M.H., Al-Arfaj. K.M., Nallasamy. N, et al. Topical bevacizumab in the treatment of corneal neovascularization: results of a prospective, open-label, noncomparative study. *Arch Ophthalmol*. 2009;127:381--9
- DeStafeno, J.J., Kim, T. 2007. Topical bevacizumab therapy for corneal neovascularization. *Arch Ophthalmol*;125: 834--6
- Ellenberg, D., Azar, D.T., Hallak, J.A., et al. 2010. Novel aspects of corneal angiogenic and lymphangiogenic privilege. *Prog Retin Eye Res*; 29:208–48.
- External Eye Disease and Corneal. AAO. 2019;11: 316-7.
- Feizi, S., Azari, A.A., Safapour, S. 2017. Therapeutic Approaches for Corneal Neovascularization. *Eye Vis*; 10;4:28.

- Feizi, S., et al. 2017. Corneal angiogenesis: Etiologies, complications, and management. Physiologic and pathologic angiogenesis - signaling mechanisms and targeted therapy. *www.intechopen.com*.
- Forooghian, F., Das, B.. 2007. Anti-angiogenic effects of ribonucleic acid interference targeting vascular endothelial growth factor and hypoxia-inducible factor-1alpha. *Am J Ophthalmol*;144(5):761–768.
- Gabison, E., Chang, J.H., Hernández-Quintela, E., et al. 2004. Antiangiogenic role of angiostatin during corneal wound healing. *Exp Eye Res*; 78:579–89.
- Ghasemi, H., Ghasanfari, T., Yaraee, R., et al. 2011. Roles of IL-8 in ocular inflammations: A review. *Ocular Immunology & Inflammation*, 19(6), 401–412.
- Gogoi, T., Deori. S., Gupta. S.. 2013. Current trend of corneal ulcer in patients attending a tertiary healthcare centre. *IJSR. ISSN (Online): 2319-7064*.
- Grisanti, S., Ziemssen, F. 2007. Bevacizumab: Off -label use in ophthalmology. *Indian J Ophthalmol*; 55:417-20.
- Gueudry, J., Richez, F., B Tougeron-Brousseau, Genevois, O., Muraine, M. 2011. Subconjunctival bevacizumab for corneal neovascularization. *J Fr Ophtalmol*; 33(9):630-6.
- Hashemian, M.N., Z-Mehrjardi, H., Moghimi, S., et al. 2011. Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats. *Ophthalmic Res*; 46:50–4.
- Hiratsuka, S., Kataoka, Y., Nakao, K., Nakamura, K., Morikawa, S., Tanaka, S., et al. 2005. Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. *Mol. Cell Biol*; 25, 355–363.
- Kampitak, K., Suntisetsin, H., Sirikul, T., 2014. Clinical and microbiological characteristics of corneal ulcers in a Thai referral center. *Asian Biomed* 8, 275–282.
- Keane, P. A., Sadda, S.R . 2012. Development of anti-VEGF therapies for intraocular use. A Guide for Clinicians. *J of Ophthalmol*.
- Khurana, A.K. 2007. Diseases of the Cornea. *Comprehensive Ophthalmology*(6 ed.). Jaypee. pp. 121–122.
- Kim, W.J., Mohan, R.R., Wilson, SE.. 1999. Effect of PDGF, IL-1alpha, and BMP2/4 on corneal fibroblast chemotaxis: expression of the platelet-derived growth factor system in the cornea. *Invest Ophthalmol Vis Sci*; 40:1364–72.
- Klettner, A., Roeder, J. 2009. Treating age-related macular degeneration-interaction of VEGF-antagonists with their target. *Mini Rev Med Chem*; 9:1127–35.
- Krachmer, J., Mannis, M., Holland E. 2005. CORNEA, 2nd ed.Elsevier Mosby; 1284-1314.

- Lee, H.T., Avraham, H., Lee, H.S., et al. 2002. Vascular Endothelial Growth Factor Modulates Neutrophil Transendothelial Migration via Up-regulation of Interleukin-8 in Human Brain Microvascular Endothelial Cells. *J Biol Chem*; 277(12):10445-51.
- Lee, P., Wang, C.C., Adamis, A.P. 1998. Ocular neovascularization: an epidemiologic review. *Surv Ophthalmol*; 43(3):245-69.
- Li, L.J., Harris, L.A. 2009. Crosstalk of VEGF and Notch pathways in tumour angiogenesis: therapeutic implications. *Frontiers in Bioscience* 14, 3094-3110.
- Lu, P., Li, L., Liu, G., et al. 2009. Enhanced experimental corneal neovascularization along with aberrant angiogenic factor expression in the absence of IL-1 receptor antagonist. *Invest Ophthalmol Vis Sci*; 50:4761-8.
- Magdalena, V., Krizova, D., Lihneova, K., et al. 2014. Treatment of Corneal Neovascularization Using Anti-VEGF Bevacizumab. *Journal of Ophthalmology*.
- Nath, R., Baruah, S., Saikia, L., et al. 2011. Mycotic corneal ulcers in upper Assam. *Indian journal of ophthalmology*; 59(5): 367-371. .
- Neufeld, G., Cohen, T., Gengrinovitch, S., Poltorak, Z. 1999. Vascular endothelial growth factor (VEGF) and its receptors. *FASEB J*; 13:9-22.
- Ozdemir, O., Altintas, O., Altintas, L., Ozkan, B., Akdag, C., Yüksel, N. 2014. Comparison of the effects of subconjunctival and topical anti-VEGF therapy (bevacizumab) on experimental corneal neovascularization. *Arq Bras Oftalmol*; 77(4):209-13.
- Pappathanassiou, M., Theodoropoulou, S., Analitis A., et al. 2013. Vascular Endothelial Growth Factor Inhibitors for Treatment of Corneal Neovascularization: A Meta-Analysis. *Cornea*; 32:435-444.
- Petsoglou, C., Balaggan, K., Dart, J.K., et al. 2013. Subconjunctival bevacizumab induces regression of corneal neovascularisation: a pilot randomised placebo-controlled double-masked trial. *Br J Ophthalmol*; 97(1):28-32.
- Qazi, Y., Maddula, S., Ambati, B. Mediator of Ocular Angiogenesis. 2009. *J. Genet*; 88, 495-515.
- Roebuck, A.K. Regulation of interleukin-8 gen expression. 1999. *Journal of interferon and cytokine research*; 19:429-438.
- Santacruz, C., Linares, M., Garfias, Y., et al. 2015. Expression of IL-8, IL-6 and IL-1 β in tears as a main characteristic of the immune response in human microbial keratitis. *Int J Mol*; 16(3):4850- 64.
- Sellers, R.S., Silverman, L., Khan, N.M. 2004. Cyclooxygenase-2 expression in the cornea of dogs with keratitis. *Veterinary Pathology*; 41(12):116:21.
- Shi, J., Wei, P.K. 2016. Interleukin-8: A potent promoter of angiogenesis in gastric cancer. *Oncology Letters* ; 11: 1043-1050.

- Shibuya, M. 2014. VEGF-VEGFR Signals in Health and Disease. *Biomol Ther* (Seoul) ; 22:1–9.
- Singh, R., Gupta, N., Vanathi, M., et al. 2019. Corneal Transplantation in The Modern Era. *Indian J Med Res* ; 150(1):7-22.
- Tran, T.M., Ritchie, H.M., Lausch, R.N., et al. 2000. Calcitonin Gene-related Peptide Induces IL-8 synthesis in Human Corneal Epithelial Cells. *J Immunol* ; 164 (8) 4307-4312.
- Xie, K. 2001. Interleukin-8 and human cancer biology. *Cytokine Growth Factor Rev.* 12(4):375–391.
- Zondor, S.D., Medina, P.J.. 2004. Bevacizumab: An angiogenesis inhibitor with efficacy in colorectal and other malignancies. *Ann Pharmacother* ; 38:1258-64.
- Zamani, M., Panahi-Bazaz, M., Assadi M. 2015. Corneal collagen cross-linking for treatment of non-healing corneal ulcers. *J Ophthalmic Vis Res*; 10(1):16.
- Zuhair, S., Walid, S. 2019. Corneal neovascularization: updates on pathophysiology, investigations & management. *Romanian Journal of Ophthalmology*; Vol 63, Issue 1, January-March. pp:15-22.